Return to Managed Care Alert Section
Reports summarize angiotensins research from M.E. Bowen and co-authors
April 28th, 2008
2008 APR 28 -- According to recent research from the United States, "The objective of the study was to identify angiotensin-converting enzyme ( ACE) inhibitor prescription-filling trends in pregnant women. This was a retrospective cohort study in women continuously enrolled in Tennessee Medicaid during pregnancy who delivered a live infant or had a fetal death between 1986-2003 (n = 262,179)." "ACE inhibitor exposures increased more than 4-fold: from 11.2 per 10,000 pregnancies in 1986-1988 to 58.9 per 10,000 pregnancies by 2003 ( adjusted risk ratio [RR], 4.49; 95% confidence interval [Cl], 2.78-7.25). Exposures in the second and third trimesters nearly tripled ( RR, 2.88; 95% Cl, 1.45-5.75) and did not decrease following a US Food and Drug Administration black box warning against such use in 1992. Exposures were most common among women 35 years of age or older. Despite evidence of fetal complications associated with ACE inhibitor use during pregnancy, the number of pregnant women with pregnancy-related ACE inhibitor exposures increased steadily between 1986-2003," wrote M.E. Bowen and colleagues. The researchers concluded: "Better methods are needed to reduce fetal exposure to potentially teratogenic prescribed medications." Bowen and colleagues published their study in American Journal of Obstetrics and Gynecology (Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. American Journal of Obstetrics and Gynecology, 2008;198(3):E1). For additional information, contact W.O. Cooper, Vanderbilt Children's Hospital, Child & Adolescent Health Research Unit, AA-0216 MCN, Nashville, TN 37232, USA. Publisher contact information for the American Journal of Obstetrics and Gynecology is: Mosby-Elsevier, 360 Park Avenue South, New York, NY 10010-1710, USA. Keywords: United States, Nashville, Angiotensins, ACE-Inhibitors, Angiotensin, Clinical Trial Research, Gynecology, Health Policy, Medicaid, Obstetrics, Pregnancy, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2008, Biotech Business Week via NewsRx.com.
Return to Managed Care Alert Section
|
